Use of Dual Energy Computed Tomography in Thoracic Radiotherapy Planning.

NCT ID: NCT04863027

Last Updated: 2022-11-16

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 60 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2015-01-31
• Study Completion Date: 2022-11-30

Brief Summary

This is a prospective observational study aiming: 1) To quantify lung function using perfusion dual energy computed tomography (DECT) and use this information at the time of treatment planning with preferential sparing of functional lung parenchymal 2) to validate results of lung function obtained using DECT with lung perfusion scintigraphy results, the current standard method; 4) to compare dosimetry of whole lungs vs. functional lungs in patients treated with either stereotactic body radiotherapy (SBRT) for early stage lung cancer or conventional radiotherapy for locally advanced lung cancer and 5) to evaluate lung function 6, 12 and 24 months post-radiotherapy with both perfusion DECT and pulmonary function tests and compare radiation dose-map to functional lung-map.

Conditions

Lung Cancer; Lung Function Decreased; Radiation Pneumonitis

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Thoracic radiotherapy

Patients will have pre-treatment and post-treatment perfusion DECT for baseline and post-treatment lung function

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

• ≥ 18 years
• ECOG 0-2
• Pulmonary neoplasia, confirmed histopathologically or by imaging
• Prognosis evaluated ≥ 1 year by attending MD
• Clinically acceptable lung capacity to undergo radiotherapy
• Initial assessment including history, physical examination, biochemistry, PFT, chest radiograph, chest and abdominal-pelvic scan, PET
• Written consent
• The patient must be available for treatment and monitoring. Patients registered in the study should be treated in our center.

Exclusion Criteria

• Previous radiotherapy in the radiation field
• Presence of any major medical condition that, in the opinion of the investigator, would prevent follow-up at 6, 12 and 24 months post-radiotherapy.
• Iodine allergy
• Pregnancy and lactation

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Varian Medical Systems

INDUSTRY

Sponsor Role: collaborator

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Centre Hospitalier de l'Université de Montréal

Montreal, Quebec, Canada

Countries

Canada

Other Identifiers

14.003

Identifier Type: -

Identifier Source: org_study_id